GSK's latecomer to the PD-1/PD-L1 inhibitor ... and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda (pembrolizumab), showing it ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment ... The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab) given with carboplatin and paclitaxel ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Feb 14 (Reuters) - Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK (GSK.L), opens new tab, the Financial Times reported on Friday. Citadel has ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Teva Pharmaceutical Industries Ltd. ADR-2.29% $19.01B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

After hours: February 14 at 6:49:49 p.m. EST ...